Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030653579> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W3030653579 endingPage "942" @default.
- W3030653579 startingPage "938" @default.
- W3030653579 abstract "Retinal neovascularization,a common pathological process of a variety of eye diseases,is a major cause of blindness.Vascular endothelial growth factor (VEGF) has been believed to be the most important therapeutic target of neovascular eye diseases.In the era of anti-VEGF for retinal diseases,several drugs aiming at the single molecular target VEGF-A have achieved considerable success in decreasing neovascularization and relieving the symptoms.In the past two years,novel anti-VEGF drugs aiming at multiple molecular targets including VEGF-A,VEGF-B and PlGF have surged into clinic service.Represented by aflibercept (VEGF Trap-Eye,Eylea) and conbercept (KH902),multiple targets anti-VEGF drugs relieve the clinical symptoms in patients resistant to single target anti-VEGF drugs.In addition,because similar curative effects are achieved with longer injection interval,risk of complications related to the intraocular injection procedure is reduced.However,it is reported that the additional inhibited targets are associated with maintaining the normal functions of blood vessels and neurons.Therefore,although there are still no severe adverse effects for these new developed drugs,further long-term observation is mandatory to evaluate their safety.In this review,we summarized the characteristics of aflibercept and conbercept,a new generation of anti-VEGF drugs,from the aspects of basic research,pharmacokinetics,efficacy,safety and the existing problems.Key words: Vascular endothelial growth factor; Age-related macular degeneration/treatment; Retina; Choroidal neovascularization/treatment; Drug" @default.
- W3030653579 created "2020-06-05" @default.
- W3030653579 creator A5064648564 @default.
- W3030653579 date "2014-10-10" @default.
- W3030653579 modified "2023-09-24" @default.
- W3030653579 title "Curative effect and safety of the new generation of anti-vascular endothelial growth factor drugs in neovascular eye diseases" @default.
- W3030653579 doi "https://doi.org/10.3760/cma.j.issn.2095-0160.2014.10.016" @default.
- W3030653579 hasPublicationYear "2014" @default.
- W3030653579 type Work @default.
- W3030653579 sameAs 3030653579 @default.
- W3030653579 citedByCount "0" @default.
- W3030653579 crossrefType "journal-article" @default.
- W3030653579 hasAuthorship W3030653579A5064648564 @default.
- W3030653579 hasConcept C118487528 @default.
- W3030653579 hasConcept C126322002 @default.
- W3030653579 hasConcept C134018914 @default.
- W3030653579 hasConcept C167734588 @default.
- W3030653579 hasConcept C197934379 @default.
- W3030653579 hasConcept C2776403814 @default.
- W3030653579 hasConcept C2776694085 @default.
- W3030653579 hasConcept C2777025900 @default.
- W3030653579 hasConcept C2777512022 @default.
- W3030653579 hasConcept C2777802072 @default.
- W3030653579 hasConcept C2778271429 @default.
- W3030653579 hasConcept C2778749236 @default.
- W3030653579 hasConcept C2779829184 @default.
- W3030653579 hasConcept C2780394083 @default.
- W3030653579 hasConcept C2781100027 @default.
- W3030653579 hasConcept C2781359195 @default.
- W3030653579 hasConcept C555293320 @default.
- W3030653579 hasConcept C71924100 @default.
- W3030653579 hasConcept C98274493 @default.
- W3030653579 hasConceptScore W3030653579C118487528 @default.
- W3030653579 hasConceptScore W3030653579C126322002 @default.
- W3030653579 hasConceptScore W3030653579C134018914 @default.
- W3030653579 hasConceptScore W3030653579C167734588 @default.
- W3030653579 hasConceptScore W3030653579C197934379 @default.
- W3030653579 hasConceptScore W3030653579C2776403814 @default.
- W3030653579 hasConceptScore W3030653579C2776694085 @default.
- W3030653579 hasConceptScore W3030653579C2777025900 @default.
- W3030653579 hasConceptScore W3030653579C2777512022 @default.
- W3030653579 hasConceptScore W3030653579C2777802072 @default.
- W3030653579 hasConceptScore W3030653579C2778271429 @default.
- W3030653579 hasConceptScore W3030653579C2778749236 @default.
- W3030653579 hasConceptScore W3030653579C2779829184 @default.
- W3030653579 hasConceptScore W3030653579C2780394083 @default.
- W3030653579 hasConceptScore W3030653579C2781100027 @default.
- W3030653579 hasConceptScore W3030653579C2781359195 @default.
- W3030653579 hasConceptScore W3030653579C555293320 @default.
- W3030653579 hasConceptScore W3030653579C71924100 @default.
- W3030653579 hasConceptScore W3030653579C98274493 @default.
- W3030653579 hasIssue "10" @default.
- W3030653579 hasLocation W30306535791 @default.
- W3030653579 hasOpenAccess W3030653579 @default.
- W3030653579 hasPrimaryLocation W30306535791 @default.
- W3030653579 hasRelatedWork W140751345 @default.
- W3030653579 hasRelatedWork W187692917 @default.
- W3030653579 hasRelatedWork W1981639930 @default.
- W3030653579 hasRelatedWork W1997026470 @default.
- W3030653579 hasRelatedWork W2069646317 @default.
- W3030653579 hasRelatedWork W2085286148 @default.
- W3030653579 hasRelatedWork W2115232314 @default.
- W3030653579 hasRelatedWork W2220589610 @default.
- W3030653579 hasRelatedWork W2333350526 @default.
- W3030653579 hasRelatedWork W2415260106 @default.
- W3030653579 hasRelatedWork W3029278076 @default.
- W3030653579 hasRelatedWork W3029688118 @default.
- W3030653579 hasRelatedWork W3030701191 @default.
- W3030653579 hasRelatedWork W3030728524 @default.
- W3030653579 hasRelatedWork W3046351430 @default.
- W3030653579 hasRelatedWork W3136974098 @default.
- W3030653579 hasRelatedWork W3185661221 @default.
- W3030653579 hasRelatedWork W3192080845 @default.
- W3030653579 hasRelatedWork W86174747 @default.
- W3030653579 hasRelatedWork W2771724388 @default.
- W3030653579 hasVolume "32" @default.
- W3030653579 isParatext "false" @default.
- W3030653579 isRetracted "false" @default.
- W3030653579 magId "3030653579" @default.
- W3030653579 workType "article" @default.